GlassScriptPhysician profile
Steven J Brooks
NPI 1073800165
$27,673.92
in general payments reported to CMS, 2019-2025
42 companies · $5,260 in 2025
The $5,260 reported for 2025 was more than what 88% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,085 · 2020: $2,189 · 2021: $3,662 · 2022: $3,990 · 2023: $2,804 · 2024: $6,685 · 2025: $5,260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,675 · Consulting Fee: $4,480 · Travel and Lodging: $400 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,674.69 |
| Consulting Fee | $4,480.00 |
| Travel and Lodging | $400.00 |
| Education | $194.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $4,085.96 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $3,159.65 | 2023-2025 | Zoryve |
| Medimetriks Pharmaceuticals, INC. | $2,366.60 | 2019-2021 | |
| Janssen Biotech, INC. | $1,617.21 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Abbvie INC. | $1,563.28 | 2019-2025 | Botox, Skyrizi, Rinvoq |
| Teladoc Health, INC. | $1,425.00 | 2022 | |
| Sun Pharmaceutical Industries INC. | $1,243.21 | 2019-2025 | Winlevi, Absorica Ld |
| Regeneron Healthcare Solutions, INC. | $1,192.69 | 2019-2025 | Dupixent |
| Amgen INC. | $1,186.83 | 2020-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $1,095.17 | 2019-2025 | Nemluvio, Aklief, Twyneo |
| Lilly USA, LLC | $965.05 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $956.29 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $931.03 | 2019-2025 | |
| Leo Pharma INC. | $876.37 | 2019-2025 | Adbry, Anzupgo |
| Incyte Corporation | $687.96 | 2021-2025 | Opzelura |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $540.42 | 2019-2025 | Cabtreo, Jublia |
| E.R. Squibb & Sons, L.L.C. | $480.61 | 2022-2025 | Sotyktu |
| Vyne Pharmaceuticals INC. | $445.31 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $411.62 | 2019-2023 | |
| Ucb, INC. | $337.86 | 2019-2025 | Bimzelx |
| Botanix Sb INC | $321.21 | 2025 | Sofdra |
| Journey Medical Corporation | $218.39 | 2019-2025 | |
| Genentech USA, INC. | $208.78 | 2019-2021 | |
| Encore Dermatology INC. | $207.61 | 2019-2020 | |
| Celgene Corporation | $163.37 | 2019 | |
| Dermira, INC. | $160.40 | 2019-2021 | |
| Merz North America, INC. | $148.14 | 2019-2022 | |
| Almirall LLC | $108.69 | 2019-2024 | Klisyri |
| Verrica Pharmaceuticals INC. | $89.88 | 2024-2025 | Ycanth |
| Genzyme Corporation | $87.87 | 2019-2024 | |
| Epi Health, LLC | $78.64 | 2019-2022 | |
| Promius Pharma LLC | $62.40 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.63 | 2024 | Spevigo |
| Organon LLC | $39.99 | 2025 | Vtama |
| Allergan, INC. | $25.21 | 2019-2020 | |
| Lnhc, INC | $23.79 | 2025 | Zelsuvmi |
| Biofrontera INC. | $21.53 | 2019 | |
| Sandoz INC. | $20.97 | 2020 | |
| Cipher Pharmaceuticals US LLC | $20.12 | 2025 | Spinosad, Natroba |
| Krystal Biotech INC | $18.96 | 2023 | Vyjuvek |
| Melinta Therapeutics, LLC | $17.79 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $14.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.